Takeda'S Exkivity Gets Approval In China For Metastatic Lung Cancer After Chemo

Takeda Pharmaceutical Co. Ltd. (TKPHF.PK,TAK) Wednesday announced that Exkivity or mobocertinib has been approved by the National Medical Products Administration of China.

Exkivity is an oral tyrosine kinase inhibitor intended for the treatment of adult patients with locally advanced non-small cell lung cancer with epidermal growth factor receptor Exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.

The company said the approval is based on the Phase 1/2 trial and has shown clinically meaningful and durable responses in patients.

Lung cancer is the most commonly diagnosed cancer in China.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route. Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie. Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.
Follow RTT